

LentiStable™



Highly efficient producer cell lines enable scalable and cost-effective manufacturing

Advantages of LentiStable™

- **High performing:**
Generates clones with high titres
- **Scalable:**
Produces large amounts of vector over extended periods
- **Reproducible:**
Eliminates variability of transient transfection processes
- **Fast:**
Automation drastically increases throughput to identify best clones
- **Economical:**
Saves cost of plasmids and transfection reagents
- **Ready-to-go:**
GMP compliant cell line


Manufacturing large quantities of lentiviral vector (LV) for late-phase clinical trials and product commercialisation remains a challenge with the commonly used transient transfection process.

Stable cell line production of LV is the best option for manufacturing as this reduces production costs and increases the overall safety and reproducibility in gene therapy.


Our LentiStable™ Solution

We have generated suspension and adherent-based stable packaging and producer cell lines using an inducible system. Packaging cell lines stably integrate some of the components of the lentiviral system (Envelope, Gag/Pol and Rev, if required) into the cell genome. Producer cell lines integrate all components (Envelope, Gag/Pol, Rev and lentiviral vector genome) into the cell genome.

From packaging to producer cell line




Our expert team can design your producer cell line in less than 10 months



LentiStable™ is the result of more than 15 years of optimisation work. Our cutting-edge, automated technologies enable us to streamline production, minimise process risks and reduce costs. Our proprietary robotic system, Cassius™, uses state-of-the-art automation to screen and isolate up to 3000 clones thereby enabling the identification of high titre lentiviral vectors producing clones in significantly reduced timelines.

Higher lentiviral vector titre is achieved using LentiStable™ compared to a traditional transient transfection process



Cassius™ robot for cell screening

Licensing Terms

Range of packages available from straight licenses for our packaging cell line to full development of producer cell lines

Intellectual Property

Extensive know-how covering transient and stable production systems
US 6,969,598 - "Methods for producing high titre vectors and compositions used in such methods"

Publications

Stewart et al., Gene Therapy (2009), Development and inducible EIAV-based lentiviral vector packaging and producer cell line
Stewart et al., Human Gene Therapy (2011), A Stable Producer Cell Line for the Manufacture of a Lentiviral Vector for Gene Therapy of Parkinson's Disease

For more information please contact:

Oxford Biomedica
+44 (0) 1865 783 000
www.oxb.com

partnering@oxb.com